Clinical trials: Teriflunomide

Multiple Sclerosis

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

• Completed
• Age: 18 years and older
• Phase 4
• Results posted

Primary Objective: To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of Participant Reported Outcomes (PROs). Secondary Objectives: To describe disease progression using PROs.

Trial name

TERI-PRO (NCT01895335)

Testing

Teriflunomide

Where

169 sites in United States, Austria and 12 more

Volunteers

1,001 people

Sponsor

Sanofi